Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010
Background/purpose Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study performed in our tertiary care showed a mean visual gain of only + 0.7 ETDRS chart letters, probably because of insufficient...
Uložené v:
| Vydané v: | Graefe's archive for clinical and experimental ophthalmology Ročník 251; číslo 11; s. 2499 - 2503 |
|---|---|
| Hlavní autori: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.11.2013
Springer Nature B.V |
| Predmet: | |
| ISSN: | 0721-832X, 1435-702X, 1435-702X |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background/purpose
Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study performed in our tertiary care showed a mean visual gain of only + 0.7 ETDRS chart letters, probably because of insufficient number of follow-up visits and injections. We report a second retrospective study of patients whose eyes were treated in the same setting, and whose first injection was performed after April 1 2010. The aim was to check if the changes in the management of AMD patients between 2010 and 2007 achieved better visual results.
Method
One hundred and twenty-two patients (125 eyes) with exudative age-related macular degeneration (AMD) were included. Age, gender, side, type of CNV, VA measured on an ETDRS chart at baseline and at 52 ± 6 weeks, the number of IVT performed, and follow-up visits were recorded. The series was compared to our former series of the year 2007. Results are expressed as means ± standard deviation. Mann–Whitney’s non-parametric test was used to compare the statistical distribution of the parameters measured. Fisher’s exact test was used for 2 × 2 categorical variables, and the chi-square test for others.
Results
In the 2010 series, the mean visual gain was +6.0 ± 11.0 l (−35 to + 34). During this period, the eyes had 5.0 ± 1.8 IVT and 7.8 ± 1.4 follow-up visits. No correlation was found between the change in VA and gender, type of CNV, age, or the numbers of IVT and visits. There was a reverse correlation between baseline VA and VA changes (
r
= −0.413,
p
< 0.0001): i.e., the higher the VA at presentation, the smaller the gain. Comparison between 2010 and 2007 showed that in 2010, patients were older (82.2 ± 7.0 vs 78.3 ± 7.0 y,
p
< 0.0001), had a better baseline VA (60.6 ± 12.7 vs 56.1 ± 14.6 l,
p
= 0.0191) and, despite the reverse correlation between change in VA and VA at presentation, visual results were better: +6.0 ± 11.0 vs +0.7 ± 11.99 l,
p
= 0.0003. In 2010, eyes received more injections: 5.0 ± 1.8 vs 3.8 ± 1.4 in 2007,
p
< 0.0001. However, the series did not differ for the number of visits, gender, side or type of CNV.
Conclusions
In 2010, monotherapy with ranibizumab for exudative AMD achieved better visual results than in 2007 in our clinical setting, despite the treatment of older patients with better baseline VA. This is probably due to the greater number of IVT performed. Alternate strategies, such as “inject and extend” or maintenance therapy, may also account for the better visual results. |
|---|---|
| AbstractList | Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study performed in our tertiary care showed a mean visual gain of only+0.7 ETDRS chart letters, probably because of insufficient number of follow-up visits and injections. We report a second retrospective study of patients whose eyes were treated in the same setting, and whose first injection was performed after April 1 2010. The aim was to check if the changes in the management of AMD patients between 2010 and 2007 achieved better visual results. One hundred and twenty-two patients (125 eyes) with exudative age-related macular degeneration (AMD) were included. Age, gender, side, type of CNV, VA measured on an ETDRS chart at baseline and at 52 ± 6 weeks, the number of IVT performed, and follow-up visits were recorded. The series was compared to our former series of the year 2007. Results are expressed as means±standard deviation. Mann-Whitney's non-parametric test was used to compare the statistical distribution of the parameters measured. Fisher's exact test was used for 2×2 categorical variables, and the chi-square test for others. In the 2010 series, the mean visual gain was +6.0±11.0 l (-35 to+34). During this period, the eyes had 5.0±1.8 IVT and 7.8±1.4 follow-up visits. No correlation was found between the change in VA and gender, type of CNV, age, or the numbers of IVT and visits. There was a reverse correlation between baseline VA and VA changes (r=-0.413, p<0.0001): i.e., the higher the VA at presentation, the smaller the gain. Comparison between 2010 and 2007 showed that in 2010, patients were older (82.2±7.0 vs 78.3±7.0 y, p<0.0001), had a better baseline VA (60.6±12.7 vs 56.1±14.6 l, p=0.0191) and, despite the reverse correlation between change in VA and VA at presentation, visual results were better: +6.0±11.0 vs +0.7±11.99 l, p=0.0003. In 2010, eyes received more injections: 5.0±1.8 vs 3.8±1.4 in 2007, p<0.0001. However, the series did not differ for the number of visits, gender, side or type of CNV. In 2010, monotherapy with ranibizumab for exudative AMD achieved better visual results than in 2007 in our clinical setting, despite the treatment of older patients with better baseline VA. This is probably due to the greater number of IVT performed. Alternate strategies, such as "inject and extend" or maintenance therapy, may also account for the better visual results.[PUBLICATION ABSTRACT] Background/purpose Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study performed in our tertiary care showed a mean visual gain of only + 0.7 ETDRS chart letters, probably because of insufficient number of follow-up visits and injections. We report a second retrospective study of patients whose eyes were treated in the same setting, and whose first injection was performed after April 1 2010. The aim was to check if the changes in the management of AMD patients between 2010 and 2007 achieved better visual results. Method One hundred and twenty-two patients (125 eyes) with exudative age-related macular degeneration (AMD) were included. Age, gender, side, type of CNV, VA measured on an ETDRS chart at baseline and at 52 ± 6 weeks, the number of IVT performed, and follow-up visits were recorded. The series was compared to our former series of the year 2007. Results are expressed as means ± standard deviation. Mann–Whitney’s non-parametric test was used to compare the statistical distribution of the parameters measured. Fisher’s exact test was used for 2 × 2 categorical variables, and the chi-square test for others. Results In the 2010 series, the mean visual gain was +6.0 ± 11.0 l (−35 to + 34). During this period, the eyes had 5.0 ± 1.8 IVT and 7.8 ± 1.4 follow-up visits. No correlation was found between the change in VA and gender, type of CNV, age, or the numbers of IVT and visits. There was a reverse correlation between baseline VA and VA changes ( r = −0.413, p < 0.0001): i.e., the higher the VA at presentation, the smaller the gain. Comparison between 2010 and 2007 showed that in 2010, patients were older (82.2 ± 7.0 vs 78.3 ± 7.0 y, p < 0.0001), had a better baseline VA (60.6 ± 12.7 vs 56.1 ± 14.6 l, p = 0.0191) and, despite the reverse correlation between change in VA and VA at presentation, visual results were better: +6.0 ± 11.0 vs +0.7 ± 11.99 l, p = 0.0003. In 2010, eyes received more injections: 5.0 ± 1.8 vs 3.8 ± 1.4 in 2007, p < 0.0001. However, the series did not differ for the number of visits, gender, side or type of CNV. Conclusions In 2010, monotherapy with ranibizumab for exudative AMD achieved better visual results than in 2007 in our clinical setting, despite the treatment of older patients with better baseline VA. This is probably due to the greater number of IVT performed. Alternate strategies, such as “inject and extend” or maintenance therapy, may also account for the better visual results. Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study performed in our tertiary care showed a mean visual gain of only + 0.7 ETDRS chart letters, probably because of insufficient number of follow-up visits and injections. We report a second retrospective study of patients whose eyes were treated in the same setting, and whose first injection was performed after April 1 2010. The aim was to check if the changes in the management of AMD patients between 2010 and 2007 achieved better visual results. One hundred and twenty-two patients (125 eyes) with exudative age-related macular degeneration (AMD) were included. Age, gender, side, type of CNV, VA measured on an ETDRS chart at baseline and at 52 ± 6 weeks, the number of IVT performed, and follow-up visits were recorded. The series was compared to our former series of the year 2007. Results are expressed as means ± standard deviation. Mann-Whitney's non-parametric test was used to compare the statistical distribution of the parameters measured. Fisher's exact test was used for 2 × 2 categorical variables, and the chi-square test for others. In the 2010 series, the mean visual gain was +6.0 ± 11.0 l (-35 to + 34). During this period, the eyes had 5.0 ± 1.8 IVT and 7.8 ± 1.4 follow-up visits. No correlation was found between the change in VA and gender, type of CNV, age, or the numbers of IVT and visits. There was a reverse correlation between baseline VA and VA changes (r = -0.413, p < 0.0001): i.e., the higher the VA at presentation, the smaller the gain. Comparison between 2010 and 2007 showed that in 2010, patients were older (82.2 ± 7.0 vs 78.3 ± 7.0 y, p < 0.0001), had a better baseline VA (60.6 ± 12.7 vs 56.1 ± 14.6 l, p = 0.0191) and, despite the reverse correlation between change in VA and VA at presentation, visual results were better: +6.0 ± 11.0 vs +0.7 ± 11.99 l, p = 0.0003. In 2010, eyes received more injections: 5.0 ± 1.8 vs 3.8 ± 1.4 in 2007, p < 0.0001. However, the series did not differ for the number of visits, gender, side or type of CNV. In 2010, monotherapy with ranibizumab for exudative AMD achieved better visual results than in 2007 in our clinical setting, despite the treatment of older patients with better baseline VA. This is probably due to the greater number of IVT performed. Alternate strategies, such as "inject and extend" or maintenance therapy, may also account for the better visual results. Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study performed in our tertiary care showed a mean visual gain of only + 0.7 ETDRS chart letters, probably because of insufficient number of follow-up visits and injections. We report a second retrospective study of patients whose eyes were treated in the same setting, and whose first injection was performed after April 1 2010. The aim was to check if the changes in the management of AMD patients between 2010 and 2007 achieved better visual results.BACKGROUND/PURPOSEVisual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study performed in our tertiary care showed a mean visual gain of only + 0.7 ETDRS chart letters, probably because of insufficient number of follow-up visits and injections. We report a second retrospective study of patients whose eyes were treated in the same setting, and whose first injection was performed after April 1 2010. The aim was to check if the changes in the management of AMD patients between 2010 and 2007 achieved better visual results.One hundred and twenty-two patients (125 eyes) with exudative age-related macular degeneration (AMD) were included. Age, gender, side, type of CNV, VA measured on an ETDRS chart at baseline and at 52 ± 6 weeks, the number of IVT performed, and follow-up visits were recorded. The series was compared to our former series of the year 2007. Results are expressed as means ± standard deviation. Mann-Whitney's non-parametric test was used to compare the statistical distribution of the parameters measured. Fisher's exact test was used for 2 × 2 categorical variables, and the chi-square test for others.METHODOne hundred and twenty-two patients (125 eyes) with exudative age-related macular degeneration (AMD) were included. Age, gender, side, type of CNV, VA measured on an ETDRS chart at baseline and at 52 ± 6 weeks, the number of IVT performed, and follow-up visits were recorded. The series was compared to our former series of the year 2007. Results are expressed as means ± standard deviation. Mann-Whitney's non-parametric test was used to compare the statistical distribution of the parameters measured. Fisher's exact test was used for 2 × 2 categorical variables, and the chi-square test for others.In the 2010 series, the mean visual gain was +6.0 ± 11.0 l (-35 to + 34). During this period, the eyes had 5.0 ± 1.8 IVT and 7.8 ± 1.4 follow-up visits. No correlation was found between the change in VA and gender, type of CNV, age, or the numbers of IVT and visits. There was a reverse correlation between baseline VA and VA changes (r = -0.413, p < 0.0001): i.e., the higher the VA at presentation, the smaller the gain. Comparison between 2010 and 2007 showed that in 2010, patients were older (82.2 ± 7.0 vs 78.3 ± 7.0 y, p < 0.0001), had a better baseline VA (60.6 ± 12.7 vs 56.1 ± 14.6 l, p = 0.0191) and, despite the reverse correlation between change in VA and VA at presentation, visual results were better: +6.0 ± 11.0 vs +0.7 ± 11.99 l, p = 0.0003. In 2010, eyes received more injections: 5.0 ± 1.8 vs 3.8 ± 1.4 in 2007, p < 0.0001. However, the series did not differ for the number of visits, gender, side or type of CNV.RESULTSIn the 2010 series, the mean visual gain was +6.0 ± 11.0 l (-35 to + 34). During this period, the eyes had 5.0 ± 1.8 IVT and 7.8 ± 1.4 follow-up visits. No correlation was found between the change in VA and gender, type of CNV, age, or the numbers of IVT and visits. There was a reverse correlation between baseline VA and VA changes (r = -0.413, p < 0.0001): i.e., the higher the VA at presentation, the smaller the gain. Comparison between 2010 and 2007 showed that in 2010, patients were older (82.2 ± 7.0 vs 78.3 ± 7.0 y, p < 0.0001), had a better baseline VA (60.6 ± 12.7 vs 56.1 ± 14.6 l, p = 0.0191) and, despite the reverse correlation between change in VA and VA at presentation, visual results were better: +6.0 ± 11.0 vs +0.7 ± 11.99 l, p = 0.0003. In 2010, eyes received more injections: 5.0 ± 1.8 vs 3.8 ± 1.4 in 2007, p < 0.0001. However, the series did not differ for the number of visits, gender, side or type of CNV.In 2010, monotherapy with ranibizumab for exudative AMD achieved better visual results than in 2007 in our clinical setting, despite the treatment of older patients with better baseline VA. This is probably due to the greater number of IVT performed. Alternate strategies, such as "inject and extend" or maintenance therapy, may also account for the better visual results.CONCLUSIONSIn 2010, monotherapy with ranibizumab for exudative AMD achieved better visual results than in 2007 in our clinical setting, despite the treatment of older patients with better baseline VA. This is probably due to the greater number of IVT performed. Alternate strategies, such as "inject and extend" or maintenance therapy, may also account for the better visual results. |
| Author | Quentel, Gabriel Cohen, Salomon Y. Ayrault, Sandrine Delahaye-Mazza, Corinne Dourmad, Pauline Dubois, Lise Nghiem-Buffet, Sylvia Tadayoni, Ramin Fajnkuchen, Franck |
| Author_xml | – sequence: 1 givenname: Salomon Y. surname: Cohen fullname: Cohen, Salomon Y. email: sycsyc75@gmail.com organization: Centre Ophtalmologique d’Imagerie et de Laser, Department of Ophthalmology, University Paris Diderot, Sorbonne Paris Cité—APHP, Hôpital Lariboisière – sequence: 2 givenname: Lise surname: Dubois fullname: Dubois, Lise organization: Centre Ophtalmologique d’Imagerie et de Laser – sequence: 3 givenname: Sandrine surname: Ayrault fullname: Ayrault, Sandrine organization: Centre Ophtalmologique d’Imagerie et de Laser – sequence: 4 givenname: Pauline surname: Dourmad fullname: Dourmad, Pauline organization: Centre Ophtalmologique d’Imagerie et de Laser – sequence: 5 givenname: Corinne surname: Delahaye-Mazza fullname: Delahaye-Mazza, Corinne organization: Centre Ophtalmologique d’Imagerie et de Laser – sequence: 6 givenname: Franck surname: Fajnkuchen fullname: Fajnkuchen, Franck organization: Centre Ophtalmologique d’Imagerie et de Laser – sequence: 7 givenname: Sylvia surname: Nghiem-Buffet fullname: Nghiem-Buffet, Sylvia organization: Centre Ophtalmologique d’Imagerie et de Laser – sequence: 8 givenname: Gabriel surname: Quentel fullname: Quentel, Gabriel organization: Centre Ophtalmologique d’Imagerie et de Laser – sequence: 9 givenname: Ramin surname: Tadayoni fullname: Tadayoni, Ramin organization: Department of Ophthalmology, University Paris Diderot, Sorbonne Paris Cité—APHP, Hôpital Lariboisière |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23604514$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1LHTEUhkOx1KvtD-imBNx0M-05Se5kxp1YPwqWQpHiLiSZMxKZm9Fkxtb7683lKhShrpLF8xzec949thPHSIx9RPiCAPprBlCoK0BZCSmbav2GLVDJZaVBXO2wBWiBVSPF1S7by_kGCi6X-I7tClmDWqJasN-_bAwurOeVdbwfE6e_c2encE_86Mc3HiK33A8hBm8HnmmaQrw-5F3oe0oUPWXuaPpDFLkoibiNXfkgvGdveztk-vD07rPL05PL4_Pq4ufZ9-Oji8or2UyV0h7B9bXCVrSKOkedLds0gK52RJZqlK0D9NC34LW3IDqnaxIOpQeQ--zzduxtGu9mypNZhexpGGykcc4GlVLNsmlxgx68QG_GOcUSbkPJtgHZ6EJ9eqJmt6LO3KawsunBPB-sAHoL-DTmnKg3PkzlXmOckg2DQTCbasy2GlOWMZtqzLqY-MJ8Hv6aI7ZOLmy8pvRP6P9Kjy_one0 |
| CitedBy_id | crossref_primary_10_1186_s12886_018_0690_9 crossref_primary_10_1089_jop_2014_0079 crossref_primary_10_1016_j_oret_2017_07_009 crossref_primary_10_2147_OPTH_S256009 crossref_primary_10_1038_s41598_019_49749_y crossref_primary_10_1007_s00347_016_0306_9 crossref_primary_10_1097_IAE_0000000000001134 crossref_primary_10_1016_j_biopha_2023_114368 crossref_primary_10_1371_journal_pone_0088203 crossref_primary_10_1007_s00417_021_05283_0 crossref_primary_10_1080_17425247_2019_1553953 crossref_primary_10_1002_phar_2079 crossref_primary_10_1097_IAE_0000000000003116 crossref_primary_10_1097_IAE_0000000000000746 crossref_primary_10_1097_IAE_0000000000000627 crossref_primary_10_1007_s00417_020_05005_y crossref_primary_10_1111_aos_12781 crossref_primary_10_1038_eye_2015_48 |
| Cites_doi | 10.1007/s00417-011-1636-6 10.1016/j.ajo.2009.04.001 10.1016/j.ajo.2008.12.005 10.1097/IAE.0b013e318207d152 10.1016/j.ophtha.2009.05.033 10.3129/i10-082 10.1111/j.1755-3768.2011.02268.x 10.1056/NEJMoa062655 10.1016/j.ophtha.2012.03.053 10.1016/j.ophtha.2008.08.012 10.1016/j.ajo.2009.04.010 10.2147/OPTH.S14684 10.1056/NEJMoa054481 10.1016/j.ajo.2007.10.004 10.1097/IAE.0b013e3181de5609 10.5301/EJO.2010.5766 10.1097/IAE.0b013e3181bfbd46 10.1016/j.ajo.2007.01.028 10.1097/IAE.0b013e3181d50cbf 10.1097/IAE.0b013e31827b6324 10.1136/bjo.2009.170670 10.1016/j.ajo.2007.02.024 10.1016/j.ophtha.2010.02.032 10.1155/2011/405724 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag Berlin Heidelberg 2013 |
| Copyright_xml | – notice: Springer-Verlag Berlin Heidelberg 2013 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s00417-013-2338-z |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1435-702X |
| EndPage | 2503 |
| ExternalDocumentID | 3105939781 23604514 10_1007_s00417_013_2338_z |
| Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .55 .86 .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 28- 29I 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3O- 3V. 4.4 406 408 409 40D 40E 53G 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 X7M YLTOR Z45 Z7U Z81 Z82 Z83 Z87 Z8O Z8U Z8V Z8W Z91 ZMTXR ZOVNA ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c438t-47c10bf6419294edbeda013801b6beeae6139b01c0f90c7ca02db76e2b13c003 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 20 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000326052700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0721-832X 1435-702X |
| IngestDate | Sun Aug 24 04:09:20 EDT 2025 Tue Nov 04 21:11:02 EST 2025 Thu Apr 03 06:56:48 EDT 2025 Sat Nov 29 03:19:48 EST 2025 Tue Nov 18 21:05:32 EST 2025 Fri Feb 21 02:42:41 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | Exudative age-related macular degeneration Real-life retrospective study Ranibizumab |
| Language | English |
| License | http://www.springer.com/tdm |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c438t-47c10bf6419294edbeda013801b6beeae6139b01c0f90c7ca02db76e2b13c003 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 |
| PMID | 23604514 |
| PQID | 1443980387 |
| PQPubID | 48614 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_1444858910 proquest_journals_1443980387 pubmed_primary_23604514 crossref_citationtrail_10_1007_s00417_013_2338_z crossref_primary_10_1007_s00417_013_2338_z springer_journals_10_1007_s00417_013_2338_z |
| PublicationCentury | 2000 |
| PublicationDate | 2013-11-01 |
| PublicationDateYYYYMMDD | 2013-11-01 |
| PublicationDate_xml | – month: 11 year: 2013 text: 2013-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationSubtitle | Incorporating German Journal of Ophthalmology |
| PublicationTitle | Graefe's archive for clinical and experimental ophthalmology |
| PublicationTitleAbbrev | Graefes Arch Clin Exp Ophthalmol |
| PublicationTitleAlternate | Graefes Arch Clin Exp Ophthalmol |
| PublicationYear | 2013 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Fung, Lalwani, Rosenfeld, Dubovy, Michels, Feuer, Puliafito, Davis, Flynn, Esquiabro (CR5) 2007; 143 Bloch, la Cour, Sander, Hansen, Fuchs, Lund-Andersen, Larsen (CR13) 2013; 91 Biarnés, Monés, Villalbí, Arias (CR12) 2011; 21 Dadgostar, Ventura, Chung, Sharma, Kaiser (CR7) 2009; 116 Spaide (CR19) 2009; 148 CR16 Cohen, Mimoun, Oubraham, Zourdani, Malbrel, Quere, Schneider (CR17) 2013; 33 Regillo, Brown, Abraham, Yue, Ianchulev, Schneider, Shams (CR4) 2008; 145 Engelbert, Zweifel, Freund (CR20) 2009; 29 Oubraham, Cohen, Samimi, Marotte, Bouzaher, Bonicel, Fajnkuchen, Tadayoni (CR23) 2011; 31 Rosenfeld, Brown, Heier, Boyer, Kaiser, Chung, Kim (CR2) 2006; 355 Querques, Azrya, Martinelli, Berboucha, Feldman, Pece, Coscas, Soubrane, Souied (CR9) 2010; 94 Gupta, Shienbaum, Patel, Fecarotta, Kaiser, Regillo (CR22) 2010; 117 Rothenbuehler, Waeber, Brinkmann, Wolf, Wolf-Schnurrbusch (CR8) 2009; 147 Martin, Maguire, Fine, Ying, Jaffe, Grunwald, Toth, Redford, Ferris (CR24) 2012; 119 Bandukwala, Muni, Schwartz, Eng, Kertes (CR10) 2010; 45 Arias, Roman, Masuet-Aumatell, Rubio, Caminal, Catala, Pujol (CR15) 2011; 31 Spaide (CR18) 2007; 143 Engelbert, Zweifel, Freund (CR21) 2010; 30 Brown, Kaiser, Michels, Soubrane, Heier, Kim, Sy, Schneider (CR3) 2006; 355 Gerding, Loukopoulos, Riese, Hefner, Timmermann (CR14) 2011; 249 Ip, Scott, Brown, Brown, Ho, Huang, Recchia (CR1) 2008; 115 Rotsos, Patel, Chen, Tufail (CR11) 2010; 10 Cohen, Dubois, Tadayoni, Fajnkuchen, Nghiem-Buffet, Delahaye-Mazza, Guiberteau, Quentel (CR6) 2009; 148 RF Spaide (2338_CR18) 2007; 143 M Biarnés (2338_CR12) 2011; 21 G Querques (2338_CR9) 2010; 94 DF Martin (2338_CR24) 2012; 119 PJ Rosenfeld (2338_CR2) 2006; 355 SY Cohen (2338_CR6) 2009; 148 OP Gupta (2338_CR22) 2010; 117 T Bandukwala (2338_CR10) 2010; 45 L Arias (2338_CR15) 2011; 31 RF Spaide (2338_CR19) 2009; 148 2338_CR16 DM Brown (2338_CR3) 2006; 355 H Gerding (2338_CR14) 2011; 249 T Rotsos (2338_CR11) 2010; 10 SP Rothenbuehler (2338_CR8) 2009; 147 H Oubraham (2338_CR23) 2011; 31 SY Cohen (2338_CR17) 2013; 33 AE Fung (2338_CR5) 2007; 143 H Dadgostar (2338_CR7) 2009; 116 M Engelbert (2338_CR21) 2010; 30 CD Regillo (2338_CR4) 2008; 145 M Engelbert (2338_CR20) 2009; 29 MS Ip (2338_CR1) 2008; 115 SB Bloch (2338_CR13) 2013; 91 17386275 - Am J Ophthalmol. 2007 Apr;143(4):679-80 19540983 - Am J Ophthalmol. 2009 Jul;148(1):1-3 21499194 - Retina. 2011 Jul-Aug;31(7):1261-7 22008284 - Acta Ophthalmol. 2013 Feb;91(1):42-7 19898180 - Retina. 2009 Nov-Dec;29(10):1424-31 23266880 - Retina. 2013 Mar;33(3):474-81 21135894 - Can J Ophthalmol. 2010 Dec;45(6):590-5 18929163 - Ophthalmology. 2008 Oct;115(10 ):1837-46 19951942 - Br J Ophthalmol. 2010 Mar;94(3):292-6 18222192 - Am J Ophthalmol. 2008 Feb;145(2):239-248 17021318 - N Engl J Med. 2006 Oct 5;355(14):1419-31 17386270 - Am J Ophthalmol. 2007 Apr;143(4):566-83 22555112 - Ophthalmology. 2012 Jul;119(7):1388-98 19643484 - Ophthalmology. 2009 Sep;116(9):1740-7 20890885 - Eur J Ophthalmol. 2011 May-Jun;21(3):282-9 20517175 - Retina. 2010 Oct;30(9):1368-75 20591490 - Ophthalmology. 2010 Nov;117(11):2134-40 22174994 - J Ophthalmol. 2011;2011:405724 21151333 - Clin Ophthalmol. 2010 Nov 10;4:1271-5 19477713 - Am J Ophthalmol. 2009 Sep;148(3):409-13 17021319 - N Engl J Med. 2006 Oct 5;355(14 ):1432-44 20890246 - Retina. 2011 Jan;31(1):26-30 19217019 - Am J Ophthalmol. 2009 May;147(5):831-7 21387180 - Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):653-62 |
| References_xml | – volume: 249 start-page: 653 year: 2011 end-page: 662 ident: CR14 article-title: Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-011-1636-6 – volume: 148 start-page: 409 year: 2009 end-page: 413 ident: CR6 article-title: Results of one-year’s treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2009.04.001 – volume: 147 start-page: 831 year: 2009 end-page: 837 ident: CR8 article-title: Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2008.12.005 – volume: 31 start-page: 1261 year: 2011 end-page: 1267 ident: CR15 article-title: One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections publication-title: Retina doi: 10.1097/IAE.0b013e318207d152 – volume: 116 start-page: 1740 year: 2009 end-page: 1747 ident: CR7 article-title: Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration publication-title: Ophthalmology doi: 10.1016/j.ophtha.2009.05.033 – volume: 45 start-page: 590 year: 2010 end-page: 595 ident: CR10 article-title: Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review publication-title: Can J Ophthalmol doi: 10.3129/i10-082 – volume: 91 start-page: 42 year: 2013 end-page: 47 ident: CR13 article-title: Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment publication-title: Acta Ophthalmol doi: 10.1111/j.1755-3768.2011.02268.x – volume: 355 start-page: 1432 year: 2006 end-page: 1444 ident: CR3 article-title: Ranibizumab versus verteporfin for neovascular age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMoa062655 – ident: CR16 – volume: 119 start-page: 1388 year: 2012 end-page: 1398 ident: CR24 article-title: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results publication-title: Ophthalmology doi: 10.1016/j.ophtha.2012.03.053 – volume: 115 start-page: 1837 year: 2008 end-page: 1846 ident: CR1 article-title: Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology publication-title: Ophthalmology doi: 10.1016/j.ophtha.2008.08.012 – volume: 148 start-page: 1 year: 2009 end-page: 3 ident: CR19 article-title: The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2009.04.010 – volume: 10 start-page: 1271 year: 2010 end-page: 1275 ident: CR11 article-title: Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration publication-title: Clin Ophthalmol doi: 10.2147/OPTH.S14684 – volume: 355 start-page: 1419 year: 2006 end-page: 1431 ident: CR2 article-title: Ranibizumab for neovascular age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMoa054481 – volume: 145 start-page: 239 year: 2008 end-page: 248 ident: CR4 article-title: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2007.10.004 – volume: 31 start-page: 26 year: 2011 end-page: 30 ident: CR23 article-title: Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration publication-title: Retina doi: 10.1097/IAE.0b013e3181de5609 – volume: 21 start-page: 282 year: 2011 end-page: 289 ident: CR12 article-title: As-needed treatment with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration publication-title: Eur J Ophthalmol doi: 10.5301/EJO.2010.5766 – volume: 29 start-page: 1424 year: 2009 end-page: 1431 ident: CR20 article-title: “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation publication-title: Retina doi: 10.1097/IAE.0b013e3181bfbd46 – volume: 143 start-page: 566 year: 2007 end-page: 583 ident: CR5 article-title: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2007.01.028 – volume: 30 start-page: 1368 year: 2010 end-page: 1375 ident: CR21 article-title: Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy publication-title: Retina doi: 10.1097/IAE.0b013e3181d50cbf – volume: 33 start-page: 474 year: 2013 end-page: 481 ident: CR17 article-title: Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice. The LUMIERE Study publication-title: Retina doi: 10.1097/IAE.0b013e31827b6324 – volume: 94 start-page: 292 year: 2010 end-page: 296 ident: CR9 article-title: Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting publication-title: Br J Ophthalmol doi: 10.1136/bjo.2009.170670 – volume: 143 start-page: 679 year: 2007 end-page: 680 ident: CR18 article-title: Ranibizumab according to need: a treatment for age-related macular degeneration publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2007.02.024 – volume: 117 start-page: 2134 year: 2010 end-page: 2140 ident: CR22 article-title: A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.02.032 – volume: 117 start-page: 2134 year: 2010 ident: 2338_CR22 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.02.032 – ident: 2338_CR16 doi: 10.1155/2011/405724 – volume: 355 start-page: 1432 year: 2006 ident: 2338_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMoa062655 – volume: 148 start-page: 409 year: 2009 ident: 2338_CR6 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2009.04.001 – volume: 143 start-page: 566 year: 2007 ident: 2338_CR5 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2007.01.028 – volume: 10 start-page: 1271 year: 2010 ident: 2338_CR11 publication-title: Clin Ophthalmol doi: 10.2147/OPTH.S14684 – volume: 30 start-page: 1368 year: 2010 ident: 2338_CR21 publication-title: Retina doi: 10.1097/IAE.0b013e3181d50cbf – volume: 21 start-page: 282 year: 2011 ident: 2338_CR12 publication-title: Eur J Ophthalmol doi: 10.5301/EJO.2010.5766 – volume: 45 start-page: 590 year: 2010 ident: 2338_CR10 publication-title: Can J Ophthalmol doi: 10.3129/i10-082 – volume: 31 start-page: 26 year: 2011 ident: 2338_CR23 publication-title: Retina doi: 10.1097/IAE.0b013e3181de5609 – volume: 148 start-page: 1 year: 2009 ident: 2338_CR19 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2009.04.010 – volume: 31 start-page: 1261 year: 2011 ident: 2338_CR15 publication-title: Retina doi: 10.1097/IAE.0b013e318207d152 – volume: 33 start-page: 474 year: 2013 ident: 2338_CR17 publication-title: Retina doi: 10.1097/IAE.0b013e31827b6324 – volume: 29 start-page: 1424 year: 2009 ident: 2338_CR20 publication-title: Retina doi: 10.1097/IAE.0b013e3181bfbd46 – volume: 115 start-page: 1837 year: 2008 ident: 2338_CR1 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2008.08.012 – volume: 91 start-page: 42 year: 2013 ident: 2338_CR13 publication-title: Acta Ophthalmol doi: 10.1111/j.1755-3768.2011.02268.x – volume: 119 start-page: 1388 year: 2012 ident: 2338_CR24 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2012.03.053 – volume: 355 start-page: 1419 year: 2006 ident: 2338_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMoa054481 – volume: 143 start-page: 679 year: 2007 ident: 2338_CR18 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2007.02.024 – volume: 147 start-page: 831 year: 2009 ident: 2338_CR8 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2008.12.005 – volume: 94 start-page: 292 year: 2010 ident: 2338_CR9 publication-title: Br J Ophthalmol doi: 10.1136/bjo.2009.170670 – volume: 145 start-page: 239 year: 2008 ident: 2338_CR4 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2007.10.004 – volume: 116 start-page: 1740 year: 2009 ident: 2338_CR7 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2009.05.033 – volume: 249 start-page: 653 year: 2011 ident: 2338_CR14 publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-011-1636-6 – reference: 19217019 - Am J Ophthalmol. 2009 May;147(5):831-7 – reference: 20890246 - Retina. 2011 Jan;31(1):26-30 – reference: 19643484 - Ophthalmology. 2009 Sep;116(9):1740-7 – reference: 19898180 - Retina. 2009 Nov-Dec;29(10):1424-31 – reference: 23266880 - Retina. 2013 Mar;33(3):474-81 – reference: 17021319 - N Engl J Med. 2006 Oct 5;355(14 ):1432-44 – reference: 18222192 - Am J Ophthalmol. 2008 Feb;145(2):239-248 – reference: 18929163 - Ophthalmology. 2008 Oct;115(10 ):1837-46 – reference: 17021318 - N Engl J Med. 2006 Oct 5;355(14):1419-31 – reference: 17386275 - Am J Ophthalmol. 2007 Apr;143(4):679-80 – reference: 19540983 - Am J Ophthalmol. 2009 Jul;148(1):1-3 – reference: 21151333 - Clin Ophthalmol. 2010 Nov 10;4:1271-5 – reference: 21387180 - Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):653-62 – reference: 21499194 - Retina. 2011 Jul-Aug;31(7):1261-7 – reference: 22174994 - J Ophthalmol. 2011;2011:405724 – reference: 21135894 - Can J Ophthalmol. 2010 Dec;45(6):590-5 – reference: 22555112 - Ophthalmology. 2012 Jul;119(7):1388-98 – reference: 22008284 - Acta Ophthalmol. 2013 Feb;91(1):42-7 – reference: 19477713 - Am J Ophthalmol. 2009 Sep;148(3):409-13 – reference: 20591490 - Ophthalmology. 2010 Nov;117(11):2134-40 – reference: 17386270 - Am J Ophthalmol. 2007 Apr;143(4):566-83 – reference: 20517175 - Retina. 2010 Oct;30(9):1368-75 – reference: 19951942 - Br J Ophthalmol. 2010 Mar;94(3):292-6 – reference: 20890885 - Eur J Ophthalmol. 2011 May-Jun;21(3):282-9 |
| SSID | ssj0004351 |
| Score | 2.151774 |
| Snippet | Background/purpose
Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007,... Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2499 |
| SubjectTerms | Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Exudates and Transudates Female Fluorescein Angiography Humans Intravitreal Injections Male Medicine Medicine & Public Health Middle Aged Ophthalmology Ranibizumab Retinal Disorders Retrospective Studies Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BFqFeyrtNKchInEAWjuONEy6oQCsOdFVVFdpb5MdEWolm2-5uVe2vr8frbEEVvXCOY1uZ8Xgy38w3AO8r7fRwaBQvLUWrSpVzK73grWw1DkvtvY6Fwj_1aFSNx_VxCrjNUlplbxOjofZTRzHyT8HxL-qKwNYv5xecukYRuppaaDyEDWIqUwPY-HowOj65rYwsYgNGIgHjQXfHPa4pVjSiOaVdFlyG_zS-_PtmuuNu3oFK4w10-OR_9_4UtpLvyfZXyvIMHmD3HB4fJXT9Bfw6Md3ETpaLM2NZcGYZXi98JAZn-0ff2aRjhvWVlGyGMWP6M-tbrASDw1LWF6PQJDOdZ4SCv4TTw4PTbz946rvAnSqqOVfa5cK2JQHEtUJv0RsCNEVuS4toMLgAtRW5E20tnHZGSG91idLmhQtW4hUMummHO8BakftCOmwNtqo0riaHsnXSSgyODtoMRP_JG5c4yak1xu9mzaYcpdSE5RuSUrPM4MP6lfMVIcd9g_d6gTTpbM6aW2lk8G79OJwqgkpMh9NFHKMqargoMtheyX-9mixKIuVRGXzsFeKPyf-1ld37t_IaNiWpYqxy3IPB_HKBb-CRu5pPZpdvk1rfAAep-3Q priority: 102 providerName: ProQuest |
| Title | Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010 |
| URI | https://link.springer.com/article/10.1007/s00417-013-2338-z https://www.ncbi.nlm.nih.gov/pubmed/23604514 https://www.proquest.com/docview/1443980387 https://www.proquest.com/docview/1444858910 |
| Volume | 251 |
| WOSCitedRecordID | wos000326052700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1435-702X dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0004351 issn: 0721-832X databaseCode: 7X7 dateStart: 19971001 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1435-702X dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0004351 issn: 0721-832X databaseCode: BENPR dateStart: 19971001 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1435-702X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004351 issn: 0721-832X databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED8NOk28bGMbkI1VRtrTJkuOk8bJ3hgD7QEqVBDqW-SPi1QJAqItQv3r8blJBuqYtL3kJf6Sffad_bv7HcCXXFk1GOiUZ4Zeq7I05kY6wStZKRxkyjkVAoWP1XCYj8fFaRPHPW293VtIMpzUXbAbUUORm2TCpb9X8cUa9Ly2y2k3js4ufgdDJiHnIvF-cS-u4xbK_FMTT5XRioW5go4GpXP05r-G-xZeNzYm218KxSa8wPodvDppUPT3cDHS9cRMFvMrbZg3Whnez10gAGf7Jz_ZpGaatRGTbIrBM_o7a1Op-IOFNd5djJ4gma4dI7T7A5wfHZ4f_OJNfgVu0ySf8VTZWJgqIyC4SNEZdJqASxGbzCBq9Kq-MCK2oiqEVVYL6YzKUJo4sf402IL1-rrGHWCViF0iLVYaqzTTtiDDsbLSSPQGDZoIRDvPpW24xykFxmXZsSaH6Sp99yVNV7mI4GtX5WZJvPG3wrvt4pXNHpz6S403tnKC5yPY63773UOQiK7xeh7KpDklVhQRbC8XvetNJhmR76QRfGtX-FHjzw3l4z-V_gQbkkQkBDfuwvrsdo6f4aW9m02mt31YU2MVvnkfej8Oh6ejfhD2B-VU86E |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aAzFeuA8CA4wELyBrjpPGCRJCE2PatLZCqEJ9s3yLVGmkY23Z6H_iP-LjxB1oYm974DmO7eRcfHy-cwF4VQojej2V00Kjt6rIU6q5ZbTmtXC9QlgrQqJwXwyH5XhcfV6DXzEXBsMqo04MitpODfrIt73hn1Ulgq0fjr9T7BqF6GpsodGyxaH7eeqvbLP3B7uevq853_s0-rhPu64C1ORZOae5MCnTdYHwZ5U7q51VCNexVBfaOeX8AVdplhpWV8wIoxi3WhSO6zQzXgb8tNfgulfjAiPIxFicp2FmodsjVhyjXlDGEURlbc3SFGM8M8r9pZAu_z4GL9i2F3DZcNzt3fnPftRduN3Z1WSnFYR7sOaa-3Bz0EUOPICvX1Qz0ZPl4pvSxBvqxJ0tbCh6TnYGu2TSEEViliiZuRAN_o7E9jFemZIuoo2g25WoxhJE-B_C6Co-ahPWm2njHgOpWWozblytXJ0XylRoLNeGa-68Eed0AixSWJqu3jq2_TiSq0rRgSmkX14iU8hlAm9Wrxy3xUYuG7wV6S87vTOT58RP4OXqsdcYCAOpxk0XYUxeYjNJlsCjlt1Wq_GswIJDeQJvI__9Mfm_tvLk8q28gI390aAv-wfDw6dwi6MUhGzOLVifnyzcM7hhfswns5PnQZ4IyCtmy99V11a9 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aHZp4GddB2AAjwQvImuOkcYKE0KCrmLZV1TShvlm-Raq0pWNtB_Sf7d_h4yQdaGJve-A5ju3E3zk-9ncuAG9yYUS3q1KaabytytKYam4ZLXkpXDcT1ooQKHwgBoN8NCqGK3DZxsKgW2WrE4OithODd-Tb3vBPihzJ1u2ycYsY9vqfzr5TrCCFTGtbTqOGyL779cMf36Yf93p-rd9y3t89_vKVNhUGqEmTfEZTYWKmywyp0CJ1VjurkLpjsc60c8r5za7QLDasLJgRRjFutcgc13FivDz4bu_AqvA2RrcDq593B8Ojq6DMJNR-xPxj1IvNqKVUWZ3BNEaPz4Ryf0Ski783xWuW7jWWNmx-_fv_8W97AOuNxU12ahF5CCuuegRrh41PwWP4dqSqsR4v5qdKE2_CE_dzbkM6dLJz2CPjiijSxo-SqQt-4h9IW1jGq1nS-LoRvJAlqrIEuf8ncHwbH7UBnWpSuWdAShbbhBtXKlemmTIFmtGl4Zo7b945HQFrV1uaJhM7FgQ5kcsc0gEg0g8vESByEcG75StndRqSmxpvtViQjUaayisgRPB6-djrEiSIVOUm89AmzbHMJIvgaQ295Wg8yTAVURrB-xaLf3T-r6k8v3kqr2DNo1Ee7A32N-EeR4EIYZ5b0Jmdz90LuGsuZuPp-ctGuAjIW8blby8MYN0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ranibizumab+for+exudative+AMD+in+a+clinical+setting%3A+differences+between+2007+and+2010&rft.jtitle=Graefe%27s+archive+for+clinical+and+experimental+ophthalmology&rft.au=Cohen%2C+Salomon+Y&rft.au=Dubois%2C+Lise&rft.au=Ayrault%2C+Sandrine&rft.au=Dourmad%2C+Pauline&rft.date=2013-11-01&rft.issn=1435-702X&rft.eissn=1435-702X&rft.volume=251&rft.issue=11&rft.spage=2499&rft_id=info:doi/10.1007%2Fs00417-013-2338-z&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0721-832X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0721-832X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0721-832X&client=summon |